Trial Profile
Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Sickle cell anaemia; Venous thromboembolism
- Focus Therapeutic Use
- 15 Apr 2019 Status changed from recruiting to discontinued.
- 15 Nov 2018 Planned number of patients changed to 25.
- 15 Nov 2018 Planned End Date changed to 30 Sep 2019.